For nearly a decade, researchers in British Columbia followed women living with HIV who had received the HPV vaccine — and what they found quietly reshapes what medicine knows about protecting the most vulnerable. Published in The Lancet HIV, this landmark nine-year study confirms that vaccination offers durable, lasting defense against HPV in immunocompromised women, a population six times more likely to contract the virus and twice as likely to die from the cancers it causes. The findings arrive at a pivotal moment, as the World Health Organization pursues the ambitious goal of eliminating c
HPV vaccine shows lasting protection for women with HIV in longest study to date
Women living with HIV face disproportionate cervical cancer mortality, with twice the death rate compared to HIV-negative women.
The protection does not evaporate after two years
Mark
So this is about whether the HPV vaccine actually works for women with HIV. What was the gap before?
Mimi
For years, doctors only had data showing the vaccine worked for about two years in HIV-positive women. After that, nobody knew. The virus suppresses immune response, so there was real uncertainty about whether protection would hold.
Luke
Right, and we should be clear: this is one study from one university. How many women were in it? The source doesn't say.
Mimi
That's a fair point. The source doesn't give us the sample size, which would help us understand how confident we should be in the findings.
Mark
But nine years is a long time to follow people. That has to count for something.
Luke
It does. But nine years of follow-up doesn't automatically mean nine years of protection. It means they checked in at nine years. The actual duration of protection could be different from the study duration.
Mimi
True. Though the fact that they found strong protection at the nine-year mark is what matters for the WHO's cervical cancer elimination goal.
Mark
Why does this matter for the WHO specifically?
Mimi
Because women with HIV are twice as likely to die from cervical cancer. If you're trying to eliminate the disease globally, you have to protect the most vulnerable populations. This study shows you can.
Luke
But we don't know yet if countries will actually use this information to change their vaccination programs. That's still ahead of us.
Mark
So this is the evidence. The action is the next step.
Mimi
Exactly. The study gives doctors and public health officials the confidence to vaccinate women living with HIV as part of elimination strategy, not as an afterthought.
Le Pouls
- Women living with HIV face a stark and long-neglected disparity: six times the HPV risk and twice the cervical cancer mortality of HIV-negative women, yet they were historically excluded from vaccine research.
- Until now, doctors had only two years of post-vaccination data for this population — a dangerously short window for a disease that unfolds across decades.
- The nine-year University of British Columbia study, published in The Lancet HIV, closes that gap with the longest evidence trail yet, confirming the vaccine's protection does not fade in immunocompromised women.
- The WHO's cervical cancer elimination target — fewer than four cases per 100,000 women annually — depends on knowing that high-risk populations can be durably protected, and this study provides that assurance.
- The question now is speed: how quickly this peer-reviewed evidence moves from journal pages into national vaccination policies for women living with HIV worldwide.
For nearly a decade, researchers in British Columbia followed women living with HIV who had received the HPV vaccine — and what they found quietly reshapes what medicine knows about protecting the most vulnerable. Published in The Lancet HIV, this landmark nine-year study confirms that vaccination offers durable, lasting defense against HPV in immunocompromised women, a population six times more likely to contract the virus and twice as likely to die from the cancers it causes. The findings arrive at a pivotal moment, as the World Health Organization pursues the ambitious goal of eliminating cervical cancer globally — a goal that cannot be reached without evidence-based strategies for those who bear the heaviest burden.
For nine years, a University of British Columbia research team followed women living with HIV who had received the HPV vaccine. Their findings, published in The Lancet HIV, represent the longest study of its kind — and they carry real consequence for millions of women whose risk has long outpaced the evidence meant to protect them.
The disparity these women face is stark. They are six times more likely to contract HPV than HIV-negative women, and twice as likely to die from the cervical cancer it can cause. For years, the vaccine existed but its durability in this population remained unknown — data simply ran out after two years, leaving doctors without the long-term assurance they needed.
This study changes that calculus. Tracking vaccinated women across nearly a decade, researchers confirmed that protection does not erode — it holds. That distinction matters enormously: it transforms the HPV vaccine from a short-term intervention into a genuine, decade-spanning strategy for women who need it most.
The stakes extend beyond individual health. The World Health Organization has committed to eliminating cervical cancer globally, defining elimination as fewer than four cases per 100,000 women per year. Reaching that threshold requires confidence that vaccination strategies will work for the highest-risk populations. Women living with HIV are precisely that population, and without durable evidence, public health programs could not confidently include them.
Published in a top-tier peer-reviewed journal, the findings carry the weight needed to shift policy. The path forward depends on how swiftly this evidence moves from research into national vaccination programs — translating a scientific confirmation into a real reduction in the cancer burden that women living with HIV have carried, disproportionately and for far too long.
For nine years, researchers at the University of British Columbia tracked women living with HIV after they received the HPV vaccine. What they found matters urgently: the vaccine works, and it keeps working. The study, published in The Lancet HIV, is the longest examination yet of how well this protection holds in a population that has historically been left out of vaccine research.
Women living with HIV face a brutal arithmetic. They are six times more likely to contract human papillomavirus than women without HIV, and twice as likely to die from the invasive cervical cancer that HPV can cause. For decades, this disparity went largely unaddressed. The vaccine existed, but nobody knew if it would actually protect the women who needed it most. Doctors had data only up to two years after vaccination. After that, the evidence simply stopped.
This study changes that. By following vaccinated women for up to nine years, researchers now have concrete evidence that the protection does not evaporate. The vaccine provides what the study calls strong, long-lasting defense against HPV infection in women living with HIV. That is not a small thing. It is the difference between a treatment that might work for a couple of years and one that can genuinely alter the trajectory of a woman's health across a decade or more.
The timing matters because the World Health Organization has set an ambitious goal: eliminate cervical cancer globally. That is not metaphorical language. It means reducing cervical cancer incidence to fewer than four cases per 100,000 women per year. To get there, countries need to know that their vaccination strategies will actually work for the populations at highest risk. Women living with HIV are exactly that population. Without evidence that the vaccine protects them durably, public health programs cannot confidently include them in elimination efforts.
The research comes from a university research team, and the findings are being released through institutional channels, which means they carry the weight of peer review and publication in a top-tier journal. The Lancet HIV does not publish studies lightly. The fact that this nine-year follow-up made it through that process signals that the evidence is solid enough to change how doctors and public health officials think about vaccination in immunocompromised populations.
What happens next depends on how quickly this evidence moves from journal pages into policy. Countries working toward cervical cancer elimination need to know that vaccinating women living with HIV is not a gesture of inclusion but a genuine intervention. The study provides that assurance. It says: vaccinate these women, and the protection will last. It says: this is not a two-year experiment. It is a real strategy for reducing the cancer burden in a population that has carried too much of it for too long.
Citations marquantes
The HPV vaccine provides strong, long-lasting protection for women living with HIV— University of British Columbia study findings
Envie de l'histoire complète ?
Lire l'original sur European AIDS Treatment Group ↗
Health & Medicine